Replies to post #168870 on Biotech Values

[Double_Bagel]

I am wondering if XNPT will be bid up today.

http://www.bloomberg.com/news/2013-10-15/xenoport-investor-clinton-group-urges-horizant-shift-ceo-change.html?cmpid=yhoo

XenoPort Inc. (XNPT), the maker of the drug Horizant to treat restless-legs syndrome, should shift spending to an experimental multiple sclerosis treatment and replace its chief executive officer, shareholder Clinton Group Inc. said in a letter to management.

Clinton Group has increased its stake in the drugmaker to more than 1.3 million shares, President Greg Taxin said in the letter today addressed to XenoPort CEO Ronald Barrett, a copy of which was obtained by Bloomberg News

[DewDiligence]

So it only took one quarter for Tecfidera sales to exceed Gilenya's U.S. sales of $273M Wow.

Tecfidera has unquestionably had a great US launch. However, the predictions of a 50% Tecfidera market share in the US I’m seeing from some analysts seem overblown; I doubt that any single MS drug will ever attain such a threshold.